Sionna Corp (SION): Growth-Adjusted P/E Ratio

Brandmark of Sionna Corp (SION)

The growth-rate undervaluation assessment demonstrates the asset's value dynamics, with the indicator currently at 0.00. Sionna Therapeutics Inc (SION) aims to disrupt the market monopoly in cystic fibrosis therapy through the creation of small molecules. Development is being conducted in synergy with scientific centers for the regeneration of cellular functions. The success of this innovative foundation depends on venture investments and FDA verdicts.

Price/Earnings to Growth Multiple: Sionna Therapeutics, Inc. (SION) for 02/08/2025 - 11/16/2026

Analytical breakdowns for Sionna Therapeutics (SION)

- stock price and consensus target price:
- stock exchange capitalization data:
General company analysis:SION - Sionna Corp
Brand item of sionnatx.com

For the biotech sector of Sionna Therapeutics Inc (SION), where the efficiency of the cystic fibrosis therapy platform optimizes capital expenditures, the calculated PEG ratio serves as an indicator of investment attractiveness. This ratio correlates the current P/E multiple with expected net income dynamics, allowing investors to determine the degree of asset undervaluation relative to its expansion rates and capture the long-term potential for value growth.

Competitors of Sionna Therapeutics Inc

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Prime Medicine, Inc.|TSHA (Taysha) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple QURE (uniQure Pharma)|Growth-Adjusted Market Cap to Net Income meiragtx.com|Price/Earnings to Growth Ratio REGENXBIO RGNX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income